Metastatic breast cancer patient initially diagnosed with HER2-low disease (IHC 1+) but progressing to HER2-positive (IHC 3+)

A 72-year-old woman, faced a dynamic journey with metastatic breast cancer, marked by changes in HER2 expression and adaptive treatment strategies.

In 2009, she was diagnosed with invasive ductal carcinoma (IDC) breast cancer, characterized by HER2-low status (IHC 1+). By 2016, the cancer had progressed, manifesting as bone metastases.
In 2019, the ABSCINT-HER2 PET/CT revealed moderate to high, heterogeneous tracer uptake in the bone. A guided biopsy of a pelvic bone metastasis prompted a recategorization from HER2-low to HER2-positive (IHC 3+, ISH +).

This shift in HER2 status led to an adaptation of the treatment plan. By 2020, a positive response was observed, reflected in a decrease in the tumor marker.

In conclusion, the case of Aisha highlighted a notable alteration in HER2 expression over time, underscoring the dynamic nature of metastatic breast cancer. The utility of ABSCINT-HER2 in guiding biopsies emerged as a valuable tool in adapting treatment strategies to the evolving molecular profile of cancer. This example reflects the nuanced approach required in managing metastatic breast cancer, emphasizing the importance of personalized and responsive care.